Furthermore, they showed that OGT has tumor suppressive activity in myeloid malignancies, especially in the presence of ASXL1 mutations (Abdel-Wahab et al. 2011; Bejar et al. 2011; Gelsi-Boyer et al. 2009; Yoshida et al. 2011). This evidence concerns the gene ASXL1 and neoplasm.